MedPath

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Phase 2
Completed
Conditions
Type 1 Diabetes Mellitus
Registration Number
NCT02527265
Lead Sponsor
Mannkind Corporation
Brief Summary

Primary Objective:

-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).

Secondary Objectives:

* To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal.

* To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.

Detailed Description

The patients are expected to participate in the study for approximately 6 to 8 weeks from Screening to final follow-up visit.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Insulin Maximum Observed Concentration (Cmax)250 minutes post-dose

Insulin Cmax after a dose of Afrezza

Secondary Outcome Measures
NameTimeMethod
Insulin Time to Reach Cmax (Tmax)250 minutes post-dose

Insulin Tmax after a dose of Afrezza

Insulin Area Under Concentration Time Curve (AUC)250 minutes post-dose

Insulin AUC after a dose of Afrezza

Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)Using PK data collected over 250 minutes post-dose of Afrezza

FDKP (inert carrier excipient) calculated half life t1/2

Trial Locations

Locations (13)

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

Barbara Davis Center for Childhood Diabetes

🇺🇸

Aurora, Colorado, United States

Yale University Hospital

🇺🇸

New Haven, Connecticut, United States

University of Florida

🇺🇸

Gainesville, Florida, United States

USF Diabetes Center

🇺🇸

Tampa, Florida, United States

Atlanta Diabetes Associates

🇺🇸

Atlanta, Georgia, United States

Van Meter Pediatric Endocrinology, P.C.

🇺🇸

Atlanta, Georgia, United States

Emory University Children's Center

🇺🇸

Atlanta, Georgia, United States

Indiana University, Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

Barry J. Reiner, MD, LLC

🇺🇸

Baltimore, Maryland, United States

Scroll for more (3 remaining)
Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.